Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Benign Prostate Hyperplasia
Development of treatment for benign prostate hyperplasia to continue in Japan
April 14th, 2005
Aeterna Zentaris Inc. (AEZS) announced the decision of its Japanese partners Shionogi & Co., Ltd., and Nippon Kayaku Co., Ltd., to push ahead with the development of cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in the benign prostate hyperplasia (BPH) indication. The decision comes on the heels of the earlier announcement by Solvay Pharmaceuticals, the company's worldwide (ex-Japan) exclusive development and marketing partner for cetrorelix, to conduct its upcoming phase 3 development in endometriosis as a primary indication. Cetrorelix, Aeterna Zentaris' lead drug in the class of LHRH antagonists, has successfully completed...
Source: Women's Health Weekly (2005-04-14)
|
